Keyphrases
Myeloma
100%
Bone Marrow
100%
Therapeutic Response
100%
Myeloma Cells
100%
Stromal Microenvironment
100%
Interleukin-6
57%
Doxorubicin
42%
Human Mesenchymal Stem Cells (hMSCs)
42%
Bone Marrow Microenvironment
42%
Bcl-xL
42%
Stromal Cells
42%
Melphalan
42%
N-Ras
28%
Cyclin D2 (CCND2)
28%
Drug Use
14%
Growth Factors
14%
Genetic Modification
14%
Hematopoietic Cells
14%
Drug Resistance
14%
Malignant Cells
14%
Cell Interaction
14%
Therapeutic Treatment
14%
Activating mutation
14%
Malignant Growth
14%
Glucocorticoid-induced Apoptosis
14%
Medicine and Dentistry
In Vitro
100%
Myeloma
100%
Treatment Response
100%
Myeloma Cell
100%
Interleukin 6
66%
Bone Marrow Microenvironment
50%
Stromal Cell
50%
Bone Marrow Stromal Cell
50%
Melphalan
50%
Doxorubicin
50%
Dexamethasone
50%
Ras
33%
Cyclin D2
33%
Cell Interaction
16%
Programmed Cell Death
16%
Glucocorticoid
16%
Gene Mutation
16%
Hematopoietic Stem Cell
16%
Myeloma Cell Line
16%
Growth Factor
16%
Drug Resistance
16%
Immunology and Microbiology
Myeloma Cell
100%
Interleukin 6
66%
Bone Marrow Microenvironment
50%
Dexamethasone
50%
Cyclin D2
33%
Growth Factor
16%
Drug Resistance
16%
Cell Interaction
16%
Glucocorticoid
16%
Gene Mutation
16%
Myeloma Cell Line
16%
Hematopoietic Cell
16%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloma
100%
Interleukin 6
50%
Doxorubicin
37%
Melphalan
37%
Dexamethasone
37%
Cyclin D2
25%
Growth Factor
12%
Glucocorticoid
12%
Drug Resistance
12%